GENFIT Share Price Börse Stuttgart
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.15 EUR | +5.13% |
|
+5.74% | +174.51% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 68Cr 78Cr 63Cr 58Cr 109.59Cr 7.47TCr 111.57Cr 746.84Cr 292.42Cr 3.71TCr 293.7Cr 287.27Cr 12TCr | P/E 2026 * |
35x | P/E 2027 * | 90.2x |
|---|---|---|---|---|---|
| Enterprise Value | 63Cr 72Cr 58Cr 54Cr 101.34Cr 6.9TCr 103.18Cr 690.65Cr 270.41Cr 3.43TCr 271.6Cr 265.66Cr 12TCr | EV / Sales 2026 * |
6.27x | EV / Sales 2027 * | 4.94x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +4.98% | ||
| 1 week | +5.74% | ||
| Current month | +32.58% | ||
| 1 month | +32.58% | ||
| 3 months | +74.13% | ||
| 6 months | +152.48% | ||
| Current year | +174.51% |
| 1 week | 12.96 |  | 14.04 |
| 1 month | 10.16 | | 14.24 |
| Current year | 5.06 | | 14.24 |
| 1 year | 3.58 | | 14.24 |
| 3 years | 3.3 | | 14.24 |
| 5 years | 2.96 | | 14.24 |
| 10 years | 2.96 | | 21.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.13% | +5.74% | - | - | 77Cr | |
| -0.80% | +5.16% | -0.70% | +12.87% | 4.89TCr | |
| -4.30% | +14.38% | +23.80% | +5.98% | 4.07TCr | |
| +4.34% | -0.21% | +408.85% | +617.52% | 3.85TCr | |
| -2.08% | -1.81% | +6.97% | +49.77% | 3.64TCr | |
| +5.56% | +11.70% | +11.64% | +51.50% | 2.84TCr | |
| -1.37% | -1.59% | - | - | 1.66TCr | |
| -0.86% | -4.45% | +32.23% | +128.66% | 1.63TCr | |
| -6.39% | -2.48% | -8.48% | -33.93% | 1.36TCr | |
| -0.06% | +3.75% | +3.81% | +9.62% | 1.36TCr | |
| Average | -0.04% | +6.06% | +59.77% | +105.25% | 2.81TCr | |
| Weighted average by Cap. | -0.20% | +7.20% | +74.87% | +125.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 12Cr 9.3Cr 8.58Cr 16Cr 1.1TCr 16Cr 110.15Cr 43Cr 546.95Cr 43Cr 42Cr 1.84TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 136.37Cr 53Cr 677.14Cr 54Cr 52Cr 2.28TCr |
| Net income | 2.29Cr 2.63Cr 2.12Cr 1.96Cr 3.69Cr 251.45Cr 3.76Cr 25Cr 9.85Cr 124.89Cr 9.89Cr 9.67Cr 419.98Cr | 68L 78.29L 63.15L 58.24L 1.1Cr 75Cr 1.12Cr 7.48Cr 2.93Cr 37Cr 2.94Cr 2.88Cr 124.83Cr |
| Net Debt | -5.11Cr -5.89Cr -4.75Cr -4.38Cr -8.25Cr -561.84Cr -8.4Cr -56Cr -22Cr -279.04Cr -22Cr -22Cr -938.38Cr | -6.62Cr -7.62Cr -6.14Cr -5.67Cr -11Cr -727.32Cr -11Cr -73Cr -28Cr -361.22Cr -29Cr -28Cr -1.21TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | €14.00 | +4.01% | 5,322 |
| 29/26/29 | €13.46 | +2.44% | 3,742 |
| 28/26/28 | €13.14 | -2.67% | 10,517 |
| 27/26/27 | €13.50 | +1.35% | 5,700 |
| 24/26/24 | €13.32 | +0.60% | 4,736 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
